Insights Archive
Why Royalty Financing Is A Smart Funding Alternative For Small Life Science Companies
Small life science companies are the driving force behind groundbreaking medical innovations that have the potential to transform lives.
Venture Debt Underwriting at SWK
Introduction The SWK underwriting process generally consists of an approximate four-week diligence period followed by an approximate four-week legal documentation process. Key steps in SWK’s process include data review, key opinion leader (“KOL”) calls, customer...
Financial Market Tumult Shows The Need For Creative Funding For Life Sciences
The Federal Reserve’s move to raise interest rates to battle inflation – now running at approximately 8% annually – has altered the risk and return for investors, resulting in substantial market volatility. While life sciences companies are in a period of great innovation, they have not been immune to the upheaval in the financial markets and need creative funding alternatives when it comes to raising capital.
Are Warrants Warranted in Venture Debt?
The primary motivation for growth stage companies to explore venture debt as a source of funding is to avoid the dilution that results from a round of equity financing. While venture debt will certainly be much less dilutive than an equity raise, prospective...
Demystifying the Covenant Setting Process
At SWK, we believe that financial covenants and the process of setting mutually agreeable covenant levels play an important role in the lender/borrower relationship. A lender's willingness to engage in the discussions and accommodate the requests outlined herein...
Beyond the Four Corners
Factors to Consider When Choosing a Lender The four corners of the credit agreement will contain all of the important contractual terms and conditions to which a lender and borrower have agreed to be bound. The language will dictate what is required of each party...
Venture Debt Without Institutional Investors
Capacity is one of the five C’s of credit which refers to a borrower’s ability to repay a loan’s principal and interest. For early-stage companies, the capacity to repay is markedly more uncertain than for larger, more established businesses. The presence of...
Covenants Need Not Be a Four-Letter Word
As underwriting standards loosen during periods when capital markets become increasingly favorable to borrowers, an easing, or outright elimination of financial covenants invariably follows. Regardless of the lending environment, credit agreements will contain...
Case Study: Holmdel Pharmaceuticals / Innopran XL (Product Purchase)
In December 2012 SWK acquired a limited partnership interest in Holmdel Pharmaceuticals Holmdel subsequently acquired the U.S. marketing authorization rights to InnoPran XL, a non-selective beta blocker using dosing technology to provide maximum active ingredient...
Case Study: Opiant (Royalty)
Narcan is the only FDA approved, intranasal Naloxone product for the treatment of opioid overdose Narcan is appropriately priced with revenue growth due to a differentiated nasal dosing and expanded distribution, not price hikes Opiant is a publicly traded drug...
Case Study: Orametrix (Structured Credit)
Orametrix was a Dallas-based, digital orthodontic company providing robotically bent and highly-accurate wire arches for braces In late 2016 the company approached SWK in need of funding to expand into the clear aligner market Upon completion of this project,...